Ibrutinib in CLL: benefit for all?
In this issue of Blood, Woyach et al1 report an update of a pivotal phase 3 trial showing the superiority of ibrutinib (Ibr)-based treatments over chemoimm
In this issue of Blood, Woyach et al1 report an update of a pivotal phase 3 trial showing the superiority of ibrutinib (Ibr)-based treatments over chemoimm
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Answer each quiz question to better understand the patient’s journey and determine the correct diagnosis. Wolters Kluwer (“we” or “us”) wants to inform you about…
This cross-sectional study assesses homologous recombination repair mutation genetic testing and associated characteristics among men with metastatic castration-resistant prostate cancer (mCRPC).
Listen to this episode from ESMO Podcasts on Spotify. ESMO Open Editor-in-Chief Giuseppe Curgliano introduces a discussion between Dr Sara Hurwitz, of the Fred Hutcinson…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.
Durvalumab monotherapy as consolidation therapy in limited-stage small cell lung cancer produced a clinical benefit in patients from the phase 3 ADRIATIC trial.
The investigational therapy IGNK001 has received orphan drug designation from the FDA for patients with acute myeloid leukemia.
Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.